HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma

BACKGROUND: Gastric cancer (GC) is a leading cause of cancer deaths worldwide. Since the approval of trastuzumab, targeted therapies are emerging as promising treatment options for the disease. This study aimed to explore the molecular segmentation of several known therapeutics targets, human epider...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Liu, Y J, Shen, D, Yin, X, Gavine, P, Zhang, T, Su, X, Zhan, P, Xu, Y, Lv, J, Qian, J, Liu, C, Sun, Y, Qian, Z, Zhang, J, Gu, Y, Ni, X
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2014
Assuntos:
Translational Therapeutics
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3950883/
https://ncbi.nlm.nih.gov/pubmed/24518603
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.61
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares